Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24760947 | 0.85 | HTT (0.33) | KMT2AHTTMAPT | |
| SCHEMBL31499108 | 0.79 | KMT2A (0.48) | KMT2AHTTDYRK1AMAPTPKM | |
| SCHEMBL15773977 | 0.79 | KMT2A (0.43) | KMT2AHTTDYRK1AMAPTPKM | |
| SCHEMBL5048238 | 0.79 | KMT2A (0.48) | KMT2AHTTDYRK1AMAPTPKM | |
| SCHEMBL30648735 | 0.76 | PLAU (0.43) | KMT2AHTTDYRK1AMAPTPKM | |
| SCHEMBL15507987 | 0.76 | HTT (0.35) | KMT2AHTTDYRK1A | |
| SCHEMBL15699752 | 0.76 | SMN1; SMN2 (0.36) | KMT2AHTTDYRK1AMAPTKDM4E | |
| SCHEMBL5046239 | 0.76 | KMT2A (0.35) | KMT2AHTTDYRK1AMAPTPKM | |
| SCHEMBL29338673 | 0.76 | S1PR1 (0.37) | KMT2AHTTDYRK1AMAPTKDM4E | |
| SCHEMBL30581539 | 0.76 | HTT (0.35) | KMT2AHTTDYRK1AMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-20 | — | — | US | disclosed |
| WO-2024032782-A1 | VACCINE ADJUVANTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO.LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313946-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| CN-117242056-A | Novel compounds useful as STING agonists and uses thereof | 北京加科思新药研发有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109942-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| WO-2022199677-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022199677-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-29 | — | — | WO | disclosed |
| US-8188139-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | JOLIDON SYNESE | 2009-08-13 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557114-B2 | Heterocyclic-substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1848694-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006082001-A1 | HETEROCYCLIC SUBSTITUTED PHENYL METHANONES AS INHIBITORS OF THE GLYCINE TRANSPORTER 1 | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203665-A1 | HETEROCYCLIC-SUBSTITUTED PHENYL METHANONES | CYP2B6, CYP2D6, CYP1A2 | KMT2A 2394/4885HTT 1734/4885DYRK1A 3785/4885 |
| US-20060178381-A1 | Heterocyclic-substituted phenyl methanones | CYP2B6, CYP2D6, CYP1A2 | KMT2A 2394/4885HTT 1734/4885DYRK1A 3785/4885 |
| US-20240199548-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | KMT2A 4533/4885HTT 4824/4885DYRK1A 4113/4885 |
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | KMT2A 3683/4885HTT 4857/4885DYRK1A 1873/4885 |
| US-20220395496-A1 | PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, HRH3 | KMT2A 563/4885HTT 1762/4885DYRK1A 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.